Savant Capital LLC Raises Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Savant Capital LLC raised its stake in United Therapeutics Co. (NASDAQ:UTHR) by 2.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 10,205 shares of the biotechnology company’s stock after buying an additional 266 shares during the quarter. Savant Capital LLC’s holdings in United Therapeutics were worth $3,601,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics in the 4th quarter valued at about $25,000. Brooklyn Investment Group purchased a new stake in United Therapeutics during the third quarter valued at approximately $33,000. Capital Performance Advisors LLP acquired a new stake in United Therapeutics in the third quarter valued at approximately $82,000. MassMutual Private Wealth & Trust FSB grew its holdings in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 58 shares during the last quarter. Finally, Values First Advisors Inc. acquired a new position in shares of United Therapeutics during the third quarter worth $90,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $353.31 on Wednesday. The company’s fifty day moving average price is $362.06 and its 200-day moving average price is $358.24. United Therapeutics Co. has a 1-year low of $210.64 and a 1-year high of $417.82. The firm has a market capitalization of $15.78 billion, a P/E ratio of 15.52, a PEG ratio of 0.92 and a beta of 0.57.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $896,950.62. This trade represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total value of $2,828,672.00. Following the completion of the sale, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,485,785.60. This represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 121,864 shares of company stock valued at $44,516,965. 11.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on UTHR. UBS Group raised their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Argus upped their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. HC Wainwright lifted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, LADENBURG THALM/SH SH upped their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $382.08.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.